NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); ...
72451596
:
Hi!Jaguai! what do you think of the the price of CYN?my cost is 0.32, can you give me some advise? i have lost big amount of money. Thank you so much.
NOTE! 1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice. 2. Do NOT open position WITHOUT chart confirmation, indicators, momentum. 3. Scale out and secure profits. 4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability. 5. I DO NOT give buy or sell advice 6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow) 7. NEVER be a blind follower. LASTLY, ...
IamBadNewz
:
@Jaguar8 Been waiting (im)patiently for a pop on CGTX given the recent conference and news of insider buying but price hasn’t reacted. Your thoughts?
$Lixte Biotechnology (LIXT.US)$ LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement Monday, 10th February at 5:00 pm PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ: LIXT), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333...
$Lixte Biotechnology (LIXT.US)$ We are offering on a reasonable best efforts basis up to 1,895,734 units (“Units”), each consisting of one share of common stock, par value $0.0001 per share (“common stock”) or one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrant”) and one and one-quarter (1.25) common stock purchase warrants to purchase one share of common stock (each, a “Common Warrant”) at an assumed public offering price of $2.11 per Unit, which was the c...
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Lixte Biotechnology Stock Forum
New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); ...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, ...
LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement
Monday, 10th February at 5:00 pm
PASADENA, CALIF., Feb. 10, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (NASDAQ: LIXT), a clinical stage pharmaceutical company, today announced that it has filed a request for withdrawal with the Securities and Exchange Commission (the "SEC") of the Company's Registration Statement on Form S-1 (No. 333...
We are offering on a reasonable best efforts basis up to 1,895,734 units (“Units”), each consisting of one share of common stock, par value $0.0001 per share (“common stock”) or one pre-funded warrant to purchase one share of common stock (“Pre-Funded Warrant”) and one and one-quarter (1.25) common stock purchase warrants to purchase one share of common stock (each, a “Common Warrant”) at an assumed public offering price of $2.11 per Unit, which was the c...
dead no volume
No comment yet